Company Portrait
Shanghai Upper Bio-tech Co., Ltd. (NEEQ: 873758), headquartered in Zhangjiang Science City Modern Medical Device Park, is a National-Level Specialized "Little Giant" Enterprise and National Intellectual Property Demonstration Enterprise committed to becoming a global innovator in intelligent Point-of-Care Testing (iPOCT).
Core Competencies:
• 20+ national/provincial-level key research projects
• 400+ intellectual property portfolio (patents/utility models/software copyrights)
• 5 national/industry/group standards participation
• 7 scientific awards and 10+ honors including National Key New Products
• Three R&D platforms: Postdoctoral Research Station, Shanghai Engineering Research Center for POCT, and Municipal Enterprise Technology Center
Key Focus Areas:
Specializing in rapid quantitative diagnostics for cardiovascular diseases, diabetic nephropathy, autoimmune disorders, reproductive health, infectious diseases and inflammatory conditions. Our 60+ instruments and reagents serve 10M+ patients annually through 1,000+ domestic and international healthcare institutions.
Industry Leadership:
• Authored three seminal monographs: POCT, iPOCT and IVD+Big Data Smart Diagnosis
• Pioneered the iPOCT framework emphasizing Precision, Automation, Cloud-connectivity and Sharing
• Developed "Smart Diagnostics + Health Big Data" ecosystem
• Implemented groundbreaking "3D Innovation" strategy integrating Instruments, Reagents and AI-powered Quality Control
Capital Markets:
As an NEEQ Innovation Tier listed company, we synergize Shanghai Free Trade Zone policies with Zhangjiang's biopharma cluster advantages. Through our "Capital-Technology-Market" tripartite strategy, we are advancing toward becoming China's leading digital diagnostics enterprise while contributing to Healthy China 2030 initiatives.
